Alice O Kamphorst

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6812431/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing. Cell, 2007, 129, 1401-1414.	28.9	3,390
2	Immunology of COVID-19: Current State of the Science. Immunity, 2020, 52, 910-941.	14.3	1,387
3	Differential Antigen Processing by Dendritic Cell Subsets in Vivo. Science, 2007, 315, 107-111.	12.6	1,214
4	Germinal Center Dynamics Revealed by Multiphoton Microscopy withÂa Photoactivatable Fluorescent Reporter. Cell, 2010, 143, 592-605.	28.9	1,026
5	Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent. Science, 2017, 355, 1423-1427.	12.6	753
6	Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 4993-4998.	7.1	614
7	An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature, 2019, 576, 465-470.	27.8	510
8	β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma. Cancer Discovery, 2019, 9, 1124-1141.	9.4	498
9	CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. Annual Review of Medicine, 2018, 69, 301-318.	12.2	432
10	Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage. Journal of Experimental Medicine, 2012, 209, 1153-1165.	8.5	429
11	A dynamic T cell–limited checkpoint regulates affinity-dependent B cell entry into the germinal center. Journal of Experimental Medicine, 2011, 208, 1243-1252.	8.5	349
12	Comparison of the toxicity profile of PDâ€1 versus PDâ€L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature. Cancer, 2018, 124, 271-277.	4.1	265
13	Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. Journal of Experimental Medicine, 2006, 203, 599-606.	8.5	232
14	Route of Antigen Uptake Differentially Impacts Presentation by Dendritic Cells and Activated Monocytes. Journal of Immunology, 2010, 185, 3426-3435.	0.8	198
15	Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. Journal of Experimental Medicine, 2014, 211, 1905-1918.	8.5	182
16	Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 21182-21187.	7.1	155
17	Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification. Cancer Cell, 2021, 39, 1594-1609.e12.	16.8	151
18	A Role for Lipid Bodies in the Cross-presentation of Phagocytosed Antigens by MHC Class I in Dendritic Cells. Immunity, 2009, 31, 232-244.	14.3	146

ALICE O KAMPHORST

#	Article	IF	CITATIONS
19	Inflammatory Flt3l is essential to mobilize dendritic cells and for T cell responses during Plasmodium infection. Nature Medicine, 2013, 19, 730-738.	30.7	134
20	The Nucleoporin Nup96 Is Required for Proper Expression of Interferon-Regulated Proteins and Functions. Immunity, 2006, 24, 295-304.	14.3	100
21	Zinc finger transcription factor zDC is a negative regulator required to prevent activation of classical dendritic cells in the steady state. Journal of Experimental Medicine, 2012, 209, 1583-1593.	8.5	98
22	Manipulating the PD-1 pathway to improve immunity. Current Opinion in Immunology, 2013, 25, 381-388.	5.5	95
23	Immune checkpoint inhibitors in advanced non–small cell lung cancer. Cancer, 2018, 124, 248-261.	4.1	94
24	Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2022, 7, 219-229.	8.1	79
25	CXCR3-CXCL9: It's All in the Tumor. Immunity, 2019, 50, 1347-1349.	14.3	69
26	Sustained antigen presentation can promote an immunogenic T cell response, like dendritic cell activation. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 15460-15465.	7.1	65
27	Antibody Effector Functions Mediated by FcÎ ³ -Receptors Are Compromised during Persistent Viral Infection. Immunity, 2015, 42, 367-378.	14.3	59
28	Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report. Cancer Immunology, Immunotherapy, 2017, 66, 45-50.	4.2	55
29	CD4 T-cell immunotherapy for chronic viral infections and cancer. Immunotherapy, 2013, 5, 975-987.	2.0	52
30	T cell receptor sequencing of activated CD8 T cells in the blood identifies tumor-infiltrating clones that expand after PD-1 therapy and radiation in a melanoma patient. Cancer Immunology, Immunotherapy, 2018, 67, 1767-1776.	4.2	51
31	Beyond adjuvants: Immunomodulation strategies to enhance T cell immunity. Vaccine, 2015, 33, B21-B28.	3.8	28
32	Innate profiles of cytokines implicated on oral tolerance correlate with low―or highâ€suppression of humoral response. Immunology, 2010, 130, 447-457.	4.4	7
33	Genetic Selection for Resistance or Susceptibility to Oral Tolerance to Ovalbumin Affects General Mechanisms of Tolerance Induction in Mice. Annals of the New York Academy of Sciences, 2004, 1029, 350-354.	3.8	6
34	Enhancing Fcl̂ ³ R-mediated antibody effector function during persistent viral infection. Science Immunology, 2018, 3, .	11.9	5
35	Dendritic Cells in Tolerance and Immunity against Pathogens. Journal of Immunology Research, 2016, 2016, 1-2.	2.2	1
36	Abstract 1317: Biomarker evaluation for PD-1 targeted therapies in non-small cell lung cancer (NSCLC) patients. Cancer Research, 2015, 75, 1317-1317.	0.9	1

#	Article	IF	CITATIONS
37	Dynamic changes in the immune infiltrate within hepatocellular carcinoma tumor correlate with response to PD-1 blockade Journal of Clinical Oncology, 2019, 37, e15644-e15644.	1.6	0
38	Preclinical studies of the anti-tumor effects of novel Avian paramyxovirus 4 (APMV-4) oncolytic viral therapy combined with vascular endothelial growth factor-C (VEGF-C) in melanoma Journal of Clinical Oncology, 2022, 40, e15050-e15050.	1.6	0